| P2093 | author name string | D P O'Brien | |
| | S E O'Connor | |
| | C Lunven | |
| | C N Berry | |
| | N Duval | |
| | A Grosset | |
| P2860 | cites work | Comparative study on heparin and a synthetic thrombin inhibitor no. 805 (MD-805*) in experimental antithrombin III-deficient animals | Q72105017 |
| | Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin | Q72544899 |
| | Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis | Q72571589 |
| | Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of a synthetic thrombin inhibitor | Q93678910 |
| | Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors | Q28294390 |
| | Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator | Q34308795 |
| | Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury | Q34576143 |
| | Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins | Q37568164 |
| | Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists | Q41452584 |
| | Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time | Q42370934 |
| | Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition | Q44921776 |
| | Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin. | Q51639994 |
| | Angioscopic Evaluation of Coronary-Artery Thrombi in Acute Coronary Syndromes | Q52480523 |
| | Properties of the factor Xa binding site on human platelets | Q67378792 |
| | Human platelet factor 4: Purification and characterization by affinity chromatography. Purification of human platelet factor 4 | Q67515652 |
| | Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis | Q68381187 |
| | Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis | Q69215660 |
| | Combined administration of aspirin and a specific thrombin inhibitor in man | Q70143606 |
| | In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor | Q70589331 |
| | The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries | Q70641947 |
| | Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries | Q70812401 |
| | Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion | Q70996213 |
| | Persistent activation of coagulation mechanism in unstable angina and myocardial infarction | Q72047945 |
| | Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis | Q72075719 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 727-733 | |
| P577 | publication date | 1996-06-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin | |
| P478 | volume | 118 | |